Key regions: France, Brazil, South Korea, India, China
Antiviral drugs have been a crucial aspect of modern medicine in treating viral infections. In Georgia, the Antiviral Drugs market has been developing at a steady pace due to various factors.
Customer preferences: Customers in Georgia have shown a preference for antiviral drugs that are affordable, effective, and have minimal side effects. They also tend to prefer drugs that are easily accessible and can be purchased without a prescription.
Trends in the market: One of the trends in the Antiviral Drugs market in Georgia is the increasing demand for drugs that treat hepatitis C. This is due to the high prevalence of hepatitis C in the country, which is estimated to be around 7% of the population. Another trend is the growing demand for antiviral drugs that treat HIV/AIDS. This is partly due to the government's efforts to combat the spread of the disease, which has resulted in increased awareness and testing.
Local special circumstances: Georgia has a relatively high prevalence of viral infections compared to other European countries. This is partly due to the country's location, which makes it a transit point for drug trafficking. Additionally, poor living conditions and inadequate healthcare facilities in some parts of the country have contributed to the spread of viral infections.
Underlying macroeconomic factors: The Antiviral Drugs market in Georgia is influenced by various macroeconomic factors. One of these is the country's healthcare system, which has undergone significant reforms in recent years. The government has increased funding for healthcare, which has resulted in improved access to healthcare services and drugs. Another factor is the country's economic growth, which has led to an increase in disposable income and a higher demand for healthcare services. Additionally, the country's strategic location has made it an attractive market for pharmaceutical companies looking to expand their operations in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
